We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Frances unveils drug regulation overhaul

Frances unveils drug regulation overhaul

July 15, 2011
CenterWatch Staff

Health minister Xavier Bertrand says new regulation will strengthen pharmacovigilance, create greater transparency and more declaration of interests at all levels of regulation and government, according to InPharm.

A controversy over the drug Mediator (benfluorex) caused distrust of pharmaceutical industry practices in France, with Servier’s alleged close connections with doctors and regulators blamed for the drug staying on the market.

Médiator was allowed to remain on the market in France long after it had been withdrawn in other European countries because of safety concerns. Servier’s drug was frequently prescribed off-label for weight loss in France until it was withdrawn in November 2009, after safety concerns were brought to light. Numerous retrospective studies have concluded that the drug could have caused from 500 to 2,000 deaths in France, mainly from damage to heart valves.

After a long public consultation, drug regulation will now be extensively overhauled. Among the many new measures will be assessments of whether or not new drugs offer real benefits over existing ones.

Healthcare professionals also will receive more education, but pharma companies will be banned from financing any continuing professional development. Pharma companies could be fined if they fail to declare relationships with other organizations, and new stricter controls on off-label prescribing will also be introduced.

Work already has begun on reviewing 19,000 drugs currently approved in France, of which 12,000 are on the market. The health minister predicts that many existing drugs will be withdrawn because they cannot demonstrate non-inferiority to other treatments.

The medicines regulator (AFSSAPS) also has been condemned in the media for its failure to act and will now be re-modeled as the National Agency for the Safety of Medicines (ANSM).

Health minister Bertrand has acknowledged “serious failures in the functioning of our drug system,” but said Servier, rather than the French government, will have to compensate victims.

Dominique Maraninchi, now head of AFSSAPS, said the newly named agency will need a 20% bigger annual budget to implement the reforms.

France’s pharmaceutical industry association LEEM has welcomed most of the proposals but has plans to restrict visits by sales representatives, and place a ban on pharma funding for medical education. LEEM said it is very worried by the proposed reforms, which it fears will create ‘uniquely restrictive practices’ in France and create rules that are incomprehensible for international companies and bad for jobs in the sector.

Europe Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing